<DOC>
	<DOC>NCT01244984</DOC>
	<brief_summary>The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with asthma.</brief_summary>
	<brief_title>A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Out patient at least 18 years of age Both genderds; females of childbearing potential must be willing to use birth control method A diagnosis of asthma at least 6 months prior to Screening A best FEV1 of at least 50% of the predicted nomal value at Screening Subjects have been receiving maintanance therapy for asthma, for at least 4 weeks prior to Screening History of lifethreating asthma Respiratory infection or oral candidiasis Asthma exacerbation within 12 weeks Concurrent respiratory disease or other disease that would confound study participation or affect subject safety Allergies to study drugs, study drugs7 excipients, medications related to study drugs Taking another investigational medication or medication prohibited for use during this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>Fluticasone furoate</keyword>
	<keyword>GW642444</keyword>
</DOC>